farnesol has been researched along with Candidiasis, Genital in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Černáková, L; Dos Santos, ALS; Falahatinejad, M; Mohammadi, SR; Nikoomanesh, F; Rafiee, M; Rodrigues, CF; Roudbary, M | 1 |
| Borges de Menezes Leite, L; Correa Amaral, A; Evangelista Araujo, D; Fernandes Costa, A; Pereira, M; Santos Cabral, M; Teles Brito, I | 1 |
2 other study(ies) available for farnesol and Candidiasis, Genital
| Article | Year |
|---|---|
Combination of Farnesol with Common Antifungal Drugs: Inhibitory Effect against
Topics: Antifungal Agents; Azoles; Candida; Candida albicans; Candidiasis, Vulvovaginal; Farnesol; Female; Fluconazole; Humans; Itraconazole | 2023 |
Development, characterization, and in vitro-in vivo evaluation of polymeric nanoparticles containing miconazole and farnesol for treatment of vulvovaginal candidiasis.
Topics: Animals; Antifungal Agents; BALB 3T3 Cells; Candida albicans; Candidiasis, Vulvovaginal; Capsules; Chitosan; Disease Models, Animal; Farnesol; Female; Mice; Mice, Inbred BALB C; Miconazole; Microbial Sensitivity Tests; Microbial Viability; Nanoparticles | 2019 |